Oxidative stress after thrombolysis-induced reperfusion in human stroke

Stroke

Volumn 41, Issue 4, 2010, Pages 653-660

  Domínguez, Carmen ^a,b   Delgado, Pilar ^a   Vilches, Angel ^a,b   Martín Gallán, Pilar ^a,b   Ribó, Marc ^a   Santamarina, Estevo ^a   Molina, Carlos ^a   Corbeto, Natalia ^a   Rodríguez Sureda, Victor ^a,b   Rosell, Anna ^a   Alvarez Sabín, Jose ^a   Montaner, Joan ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

AOPPs; MDA; MPO; Oxidative stress; Stroke; Thrombolysis

Indexed keywords

BIOLOGICAL MARKER; MALONALDEHYDE; MYELOPEROXIDASE; PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

AGED; ARTICLE; BLOOD CLOT LYSIS; BLOOD LEVEL; BLOOD SAMPLING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL ASSESSMENT; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; FEMALE; HUMAN; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; MIDDLE CEREBRAL ARTERY; MIDDLE CEREBRAL ARTERY OCCLUSION; MOLECULE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; ONSET AGE; OXIDATION; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; RECANALIZATION; REPERFUSION; STROKE; TREATMENT OUTCOME;

AGED; ANIMALS; BIOLOGICAL MARKERS; CEREBRAL HEMORRHAGE; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; PEROXIDASE; REACTIVE OXYGEN SPECIES; REPERFUSION; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 77950261039     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.571935     Document Type: Article

References (35)

1. Halliwell B Gutteridge JMC. Free Radicals in Biology and Medicine. Oxford UK: Clarendon Press; 1999.
2. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet. 1994;344:721-724.
3. Halliwell B, Whiteman M. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br J Pharmacol. 2004;142:231-255.
4. Schaller B, Graf R. Cerebral ischemia and reperfusion: the pathophysi-ologic concept as a basis for clinical therapy. J Cereb Blood Flow Metab. 2004;24:351-371.
5. Fabian RH, Dewitt DS, Kent TA. In vivo detection of superoxide anion production by the brain using a cytochrome c electrode. J Cereb Blood Flow Metab. 1995;15:242-247.
6. Peters O, Back T, Lindauer U, Busch C, Megow D, Dreier J, Dirnagl U. Increased formation of reactive oxygen species after permanent and reversible middle cerebral artery occlusion in the rat. J Cereb Blood Flow Metab. 1998;18:196-205.
7. Yamato M, Egashira T, Utsumi H. Application of in vivo ESR spec-troscopy to measurement of cerebrovascular ROS generation in stroke. Free Radic Biol Med. 2003;35:1619-1631.
8. Heo JH, Han SW, Lee SK. Free radicals as triggers of brain edema formation after stroke. Free Radic Biol Med. 2005;39:51-70.
9. Warach S, Latour LL. Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal ischemia using a novel imaging biomarker of early blood-brain barrier disruption. Stroke. 2004;35(suppl 1):2659-2661.
10. Kidwell CS, Latour L, Saver JL, Alger JR, Starkman S, Duckwiler G, Jahan R, Vinuela F, Kang DW, Warach S. Thrombolytic toxicity: blood-brain barrier disruption in human ischemic stroke. Cerebrovascular Dis. 2008;25:338-343.
11. Cano CP, Bermudez VP, Atencio HE, Medina MT, Anilsa A, Souki A, Molina OM, Restrepo H, Vargas ME, Nunez M, Ambard M, Toledo A, Contreras F, Velasco M. Increased serum malondialdehyde and decreased nitric oxide within 24 hours of thrombotic stroke onset. Am J Ther. 2003;10:473-476.
12. Demirkaya S, Topcuoglu MA, Aydin A, Ulas UH, Isimer AI, Vural O. Malondialdehyde, glutathione peroxidase and superoxide dismutase in peripheral blood erythrocytes of patients with acute cerebral ischemia. Eur J Neurol. 2001;8:43-51.
13. Polidori MC, Cherubini A, Stahl W, Senin U, Sies H, Mecocci P. Plasma carotenoid and malondialdehyde levels in ischemic stroke patients: relationship to early outcome. Free Radic Res. 2002;36:265-268.
14. Re G, Azzimondi G, Lanzarini C, Bassein L, Vaona I, Guarnieri C. Plasma lipoperoxidative markers in ischaemic stroke suggest brain embolism. Eur J Emerg Med. 1997;4:5-9.
15. Sharpe PC, Mulholland C, Trinick T. Ascorbate and malondialdehyde in stroke patients. Ir J Med Sci. 1994;163:488-491.
16. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, scamps-Latscha B. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996;49:1304-1313.
17. Lau D, Baldus S. Myeloperoxidase and its contributory role in inflammatory vascular disease. Pharmacol Ther. 2006;111:16-26.
18. Matsuo Y, Onodera H, Shiga Y, Nakamura M, Ninomiya M, Kihara T, Kogure K. Correlation between myeloperoxidase-quantified neutrophil accumulation and ischemic brain injury in the rat. Effects of neutrophil depletion. Stroke. 1994;25:1469-1475.
19. Takizawa S, Aratani Y, Fukuyama N, Maeda N, Hirabayashi H, Koyama H, Shinohara Y, Nakazawa H. Deficiency of myeloperoxidase increases infarct volume and nitrotyrosine formation in mouse brain. J Cereb Blood Flow Metab. 2002;22:50-54.
20. Hoy A, Leininger-Muller B, Poirier O, Siest G, Gautier M, Elbaz A, Amarenco P, Visvikis S. Myeloperoxidase polymorphisms in brain infarction. Association with infarct size and functional outcome. Atherosclerosis. 2003;167:223-230.
21. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41.
22. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991;337:1521-1526.
23. Brott TG, Haley EC Jr, Levy DE, Barsan W, Broderick J, Sheppard GL, Spilker J, Kongable GL, Massey S, Reed R. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke. 1992;23:632-640.
24. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH, Hennerici M; ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasmin-ogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). J Am Med Assoc. 1995;274:1017-1025.
25. Pessin MS, del Zoppo GJ, Estol CJ. Thrombolytic agents in the treatment of stroke. Clin Neuropharmacol. 1990;13:271-289.
26. Demchuk AM, Burgin WS, Christou I, Felberg RA, Barber PA, Hill MD, Alexandrov AV. Thrombolysis in brain ischemia (TIBI) transcranial Doppler flow grades predict clinical severity, early recovery, and mortality in patients treated with intravenous tissue plasminogen activator. Stroke. 2001;32:89-93.
27. Martin-Gallan P, Carrascosa A, Gussinye M, Dominguez C. Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic Biol Med. 2003;34:1563-1574.
28. Martin-Gallan P, Carrascosa A, Gussinye M, Dominguez C. Changes in oxidant-antioxidant status in young diabetic patients from clinical onset onwards. J Cell Mol Med. 2007;11:1352-1366.
29. Beckman JS, Ye YZ, Chen J, Conger KA. The interactions of nitric oxide with oxygen radicals and scavengers in cerebral ischemic injury. Adv Neurol. 1996;71:339-350.
30. Ozkul A, Akyol A, Yenisey C, Arpaci E, Kiylioglu N, Tataroglu C. Oxidative stress in acute ischemic stroke. J Clin Neurosci. 2007;14: 1062-1066.
31. Feng YH, Hart G. In vitro oxidative damage to tissue-type plasminogen activator: a selective modification of the biological functions. Cardiovasc Res. 1995;30:255-261.
32. Saqqur M, Tsivgoulis G, Molina CA, Demchuk AM, Siddiqui M, varez-Sabin J, Uchino K, Calleja S, Alexandrov AV. Symptomatic intra-cerebral hemorrhage and recanalization after IV rt-PA: a multicenter study. Neurology. 2008;71:1304-1312.
33. Hacke W, Donnan G, Fieschi C, Kaste M, von KR, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768-774.
34. Chang CY, Lai YC, Cheng TJ, Lau MT, Hu ML. Plasma levels of antioxidant vitamins, selenium, total sulfhydryl groups and oxidative products in ischemic-stroke patients as compared to matched controls in Taiwan. Free Radic Res. 1998;28:15-24.
35. Mutlu-Türkoglu U, Ilhan E, Oztezcan S, Kuru A, Aykaç-Toker G, Uysal M. Age-related increases in plasma malondialdehyde and protein carbonyl levels and lymphocyte DNA damage in elderly subjects. Clin Biochem. 2003; 397-400.